Imkeldi — CareFirst (Caremark)
Chronic Eosinophilic Leukemia (CEL)
Preferred products
- Gleevec
- imatinib mesylate
Initial criteria
- Diagnosis of HES/CEL
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months